Genetic polymorphism of CYP2D6 in North Indian subjects

Lamba, Vishal; Lamba, Jatinder K.; Dilawari, J. B.; Kohli, Krishan K.

doi:10.1007/s002280050552

Cited by 26 publications

(20 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[20] The prevalence of PMs in Western Indian population was found to be similar to that of other populations including North and South Indians [Figure 2]. [31011121316] In contrast to our study, which shows a low percentage of Western Indians being PMs, studies done in South Africa, Estonia and Poland show a higher proportion of PMs (9.4-18%)[2122] and South East Asian studies done in China and Korea show an extremely low percentage of PMs (0.6-0.7%). [2324] In this study, we did not find any ultra-rapid metabolizing phenotype.…”

Section: Discussionmentioning

confidence: 76%

See 1 more Smart Citation

Evaluation of cytochrome P450 2D6 phenotyping in healthy adult Western Indians

et al. 2014

View full text Add to dashboard Cite

Background:Cytochrome P450 2D6 (CYP2D6) metabolizes around 25% of the drugs used in therapeutics and different polymorphisms have been identified in various populations. This study aimed at finding the prevalence of CYP2D6 polymorphisms using dextromethorphan as a probe drug.Materials and Methods:Healthy participants were administered 60 mg dextromethorphan after an overnight fast and 5 ml of blood was collected 3 h postdose. A validated laboratory method was used to measure both dextromethorphan and its active metabolite, dextrorphan from plasma. Metabolic ratio (MR) of dextromethorphan to dextrorphan was calculated for each of the participants. Probit analysis was done and antimode was defined. Individuals with log MR equal to or higher than the antimode were classified as poor metabolizers (PMs) and those with values less than antimode were categorized as extensive metabolizers (EMs).Results:Data from a total of 149 participants were evaluated and the median (range) of MR was 0.25 (0.03-3.01). The polynomial equation obtained in probit analysis gave an antimode for MR of 1.39. Five (3.36%) participants were PMs and 144 (96.64%) were found to be EMs. One participant had reported mild drowsiness 2 h postdose that subsided spontaneously without any intervention.Conclusion:The prevalence of CYP2D6 polymorphism in Western Indian population is low (3.36%) and is similar to other populations.

show abstract

Section: Discussionmentioning

confidence: 76%

“…[1011121314] Since, there is a lacuna of information from Western Indian population, the present study was envisaged in healthy adults to evaluate the polymorphism of CYP2D6 using dextromethorphan as a probe drug.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of cytochrome P450 2D6 phenotyping in healthy adult Western Indians

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The PM alleles, *3, *4, and *5, were present at low frequencies, leading to the suggestion that PM rates in the South Indian states are below 5%. PM in North India has been reported to occur at a frequency of 3% [13] in contrast to South India. In one of the studies from north Delhi on schizophrenia, the frequency of CYP2D6*4 in the general population was G = 0.881; A = 0.119, comparable to the report of a Spanish population but notably different from reports of other populations (German, Saudi Arabian, Zimbabwean, Ethiopians and Chinese [14]).…”

Section: Discussionmentioning

confidence: 99%

Impact of CYP2D6 and CYP3A4 Genetic Polymorphism on Combined Cholinesterase Inhibitors and Memantine Treatment in Mild to Moderate Alzheimer's Disease

Nirmal

Tripathi²,

Sagar³

et al. 2013

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

Aim: The impact of CYP2D6 and CYP3A4 polymorphism on the steady-state plasma concentrations and therapeutic outcome of donepezil monotherapy and combination therapy in Alzheimer's disease (AD) patients. Methods: A total of 38 patients for donepezil and 17 patients for donepezil and memantine therapy, aged ≥55 years, were recruited meeting inclusion and exclusion criteria. Polymerase chain reaction-restriction fragment length polymorphism was performed. The liquid chromatography-tandem mass spectrometry method was used for estimation of drug levels of donepezil and memantine. Results: Significant allele frequency was observed for CYP2D6*3 polymorphism in patients on donepezil monotherapy and combination therapy. Significant allele frequency for CYP2D6*4 was observed in the patients on donepezil monotherapy. Conclusion: CYP2D6 polymorphism, though not significant, might partially be involved in the plasma concentration of AD drug.

show abstract

“…Conversely, the prevalence of PMs in Asian populations is relatively low, particularly among Thai, Chinese, and Japanese populations (0%-1.2%) [27][28][29]. The prevalence of the PM phenotype is slightly higher among Asians in the Indian subcontinent than in the Asian populations of southeastern and eastern Asia, with frequencies of 1.8%-4.8% reported [30][31][32][33].…”

Section: Pm Phenotypementioning

confidence: 99%

Interethnic Differences in Genetic Polymorphisms of CYP2D6 in the U.S. Population: Clinical Implications

et al. 2006

View full text Add to dashboard Cite

After completing this course, the reader will be able to:1. List the four different genotypes for CYP2D6 polymorphism.2. Understand the potential effects of CYP2D6 polymorphism on the efficacy and safety for drugs metabolized via this enzyme.3. List the ethnic groups that are most frequently affected by genetic variation of the CYP2D6 enzyme. Access and take the CME test online and receive 1 AMA PRA category 1 credit at CME.TheOncologist.com CME CME This material is protected by U.S.

show abstract

Genetic polymorphism of CYP2D6 in North Indian subjects

Abstract: From this study, it can be concluded that the PM phenotype of CYP2D6 occurs with a frequency of 3% (95% confidence interval of 0.33%-6.33%) in North Indians.

Cited by 26 publications

References 18 publications

Evaluation of cytochrome P450 2D6 phenotyping in healthy adult Western Indians

Evaluation of cytochrome P450 2D6 phenotyping in healthy adult Western Indians

Impact of CYP2D6 and CYP3A4 Genetic Polymorphism on Combined Cholinesterase Inhibitors and Memantine Treatment in Mild to Moderate Alzheimer's Disease

Interethnic Differences in Genetic Polymorphisms of CYP2D6 in the U.S. Population: Clinical Implications

Contact Info

Product

Resources

About